Overview:
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs and has become a global disease burden. It is curable and preventable. Market players are focusing on developing medications that can reduce the duration of treatment and help address the challenges of drug-resistant and drug-sensitive TB. TB treatment is divided into two types, namely first-line, second-line, and drug-resistant treatment.
Get FREE Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/191
Moreover, introduction of novel therapies and advanced technologies are expected to shorten the duration of TB treatment, however, most TB cases require up to 6 months of treatment. However, despite ongoing drugs and innovations in existing drugs, there is a need to improve patient access to appropriate TB drugs, especially in the areas of multidrug-resistant TB (MDR TB) and pediatric TB.
Drivers:
Increasing research and development activities and introduction of novel drugs is expected to boost the growth of the global tuberculosis drugs market over the forecast period. For instance, in August 2019, the U.S. Food and Drug Administration (FDA) approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant TB of the lungs. FDA granted the approval of Pretomanid Tablets to The Global Alliance for TB Drug Development (TB Alliance).
Furthermore, market players are adopting various strategies, such as collaborations, to launch novel drugs in the market. For instance, in April 2019, TB Alliance and Mylan collaborated to make the experimental drug Pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).
Moreover, increasing prevalence of tuberculosis around the world is expected to propel growth of the global tuberculosis drugs market during the forecast period. For instance, according to the World Health Organizationโs (WHOโs) global TB report, in 2017, around 10 million people around the world suffered from tuberculosis.
๐๐ต๐ฟ๐ถ๐๐๐บ๐ฎ๐ ๐ฆ๐ฎ๐น๐ฒ ๐๐ ๐๐ถ๐๐ฒ!
๐๐๐ ๐ก๐ผ๐ ๐ง๐ผ ๐๐๐ฎ๐ถ๐น ๐๐ถ๐๐ฐ๐ผ๐๐ป๐ ๐๐ฟ๐ผ๐บ ๐ฎ๐ฑ-๐ฏ๐ฌ% ๐๐ถ๐น๐น ๐ฏ๐ญ-๐๐ฒ๐ฐ-๐ฎ๐ฌ๐ฎ๐ญ
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/191
Market Taxonomy:
By Therapy Type:
- First Line Therapy
- Second Line Therapy
By Disease Type:
- Active TB
- Latent TB
By End User:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Restraints:
High cost of drugs and increase in product/drug recalls is expected to hamper the growth of the global tuberculosis drugs market. For instance, in 2018, Sandoz recalled its batch of wrongly-packed TB drugs in India. Moreover, in March 2016, the FDA recalled a batch of TB drug manufactured by Novartis due to insufficient amount of rifampicin in the drug.
Regional Insights:
Among region, North America and Europe are expected to witness robust growth in the global tuberculosis drugs market, owing to the increasing prevalence of tuberculosis in these regions. For instance, according to the TB Europe Coalition, about 323,000 new cases of TB and 32,000 deaths were reported in Europe in 2015.
Competitive Landscape:
Key players active in the global tuberculosis drugs market are Pfizer Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceuticals Ltd., Lupin Ltd, and Johnson & Johnson Services, LLC, among others.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/191
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Tuberculosis Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Tuberculosis Drugs Industry Impact
Chapter 2 Global Tuberculosis Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Tuberculosis Drugs (Volume and Value) by Type
2.3 Global Tuberculosis Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Tuberculosis Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Tuberculosis Drugs Market Analysis
Chapter 6 East Asia Tuberculosis Drugs Market Analysis
Chapter 7 Europe Tuberculosis Drugs Market Analysis
Chapter 8 South Asia Tuberculosis Drugs Market Analysis
Chapter 9 Southeast Asia Tuberculosis Drugs Market Analysis
Chapter 10 Middle East Tuberculosis Drugs Market Analysis
Chapter 11 Africa Tuberculosis Drugs Market Analysis
Chapter 12 Oceania Tuberculosis Drugs Market Analysis
Chapter 13 South America Tuberculosis Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Tuberculosis Drugs Business
Chapter 15 Global Tuberculosis Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837